Casual Films Celebrated Among Winners – KuCoin’s Brand Film Wins Top Honors at the 2025 MUSE Creative Awards: Season 2

The 2025 MUSE Creative and Design Awards, organized by the International Awards Associate (IAA), has officially announced its Season 2 results, marking the second chapter of this year's global competition while celebrating the program's 10th anniversary milestone. From more than 13,000 submissions, this season's winners embody innovation, craft, and influence across the creative and design […]

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO(R) (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

(NASDAQ:SWTX), STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO(R) (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment,

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

(NASDAQ:SPRO),(NYSE:GSK),(LSE:GSK.L), Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1 Data will be shared with regulatory authorities to support regulatory filings CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today

Caledonia Mining Corporation Plc Third Quarter Production at Blanket Mine

(NYSE MKT:CMCL),(LSE – AIM:CMCL),(LSE:CMCL.L),(LSE:CMCL.LN), ST HELIER, Jersey, Oct. 21, 2025 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (NYSE AMERICAN, AIM and VFEX: CMCL) (“Caledonia” or “the Company”) announces gold production from the Blanket Mine in Zimbabwe (“Blanket”) for the quarter ended September 30, 2025 (“Q3 2025” or the “Quarter”). All production numbers are expressed on

Singapore’s largest industrial district cooling system begins operations to support STMicroelectronics’ decarbonization strategy

(Paris:STMPA),(NYSE:STM), Singapore's largest industrial district cooling system begins operationsto support STMicroelectronics' decarbonization strategy Designed, built, owned, and operated by a joint venture between SP Group and Daikin Airconditioning (Singapore), the innovative district cooling system will significantly improve the environmental performance of ST's high-volume semiconductor manufacturing site in Singapore New system expected to reduce carbon emissions

Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq’s securities under a single ISIN

(LSE – AIM:AMRQ),(Iceland:AMRQ),(TSX-V:AMRQ),(OTC US:AMRQF),(OTCQX:AMRQF), Reykjavík, Oct. 21, 2025 (GLOBE NEWSWIRE) — Amaroq Ltd.(“Amaroq” or the “Company”) Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq's securities under a single ISIN TORONTO, ONTARIO – 21 October 2025 – Amaroq Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ, OTCQX: AMRQF), announces that its Icelandic Depositary Receipts

Progress on share buyback programme

(Euronext Amsterdam:INGA),(Brussels:INGA), Progress on share buyback programme ING announced today that, as part of our EUR2.0 billion share buyback programme announced on 2 May 2025, in total 4,381,000 shares were repurchased during the week of 13 October 2025 up to and including 17 October 2025. The shares were repurchased at an average price of EUR20.91

Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR)

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / NEW YORK, NY / ACCESS Newswire / October 21, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO(R) (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO(R) (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid

Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq’s securities under a single ISIN

Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq's securities under a single ISIN GlobeNewswire October 21, 2025 Reykjavík, Oct. 21, 2025 (GLOBE NEWSWIRE) — Amaroq Ltd.(“Amaroq” or the “Company”) Notice to holders of Icelandic Depository Receipts Simplification and streamlining of Amaroq's securities under a single ISIN TORONTO, ONTARIO – 21 October

Scroll to Top